Fundraising Fox
🦊/Companies
Sign in

Soligenix

NASDAQ: SNGX

Princeton, US · Delaware corporation · 1 known investors

Find your way into Soligenix

12 people in our graph share verified history with the Soligenix team — schools, employers, funds. One of them is your warm intro.

Nektar Baziotisunlockedknows Christopher J. Schaber, PhD · together at National Small Business Association (overlapped)
×5knows the team · via National Small Business Association
×4knows the team · via BioNJ
×2knows the team · via SOLIGENIX, INC.

Soligenix is a biopharmaceutical company developing treatments for rare diseases, with programs in photodynamic therapy for cutaneous T-cell lymphoma and psoriasis, immunomodulatory drugs for inflammatory conditions, and vaccine candidates for infectious diseases. The company operates through two segments: Specialized BioTherapeutics, focused on advancing HyBryte and related therapies toward commercialization, and Public Health Solutions, which develops vaccines and therapeutics supported primarily by government contracts.

Biotech

Founders & leadership

RCRichard C. Straube, MD MSc
Richard C. Straube, MD MScExecutive
KK
Karen KrumeichExecutive
OD
Oreola Donini, PhDExecutive
CJChristopher J. Schaber, PhD
Christopher J. Schaber, PhDinExecutiveChristopher J. Schaber holds a PhD in Pharmaceutical Sciences and an MS in Pharmaceutics, with undergraduate degrees in Business and Economics; he has held executive leadership roles in the biopharmaceutical industry for over 35 years and currently serves as Chairman, President and CEO of Soligenix, Inc.
CJ
Christopher J. SchaberinChairman of the Board, Chief Executive Officer and President
AT
Adam T. RumageNamed on SEC filing
RC
R. Christopher Cavalli, PhDNamed on SEC filing
MM
Marco M. Brughera, DVMNamed on SEC filing

Board

KL
Keith L. Brownlie, CPABoard director
JB
Jerome B. Zeldis, PhDBoard director
GA
Gregg A. LaPointe, CPABoard director
RJ
Robert J. Rubin, MDBoard director

Investors · 1

Pontifax Venture CapitalHerzeliya · $6.3M – $128M

Reported raises · per SEC filings

Form D private placements

$2M disclosed across 1 round · 2017

▶$2MraisedNov 2017 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Adam T. RumageExecutive Officer
  • Richard C. Straube, MD MScExecutive Officer
  • Karen KrumeichExecutive Officer
  • Oreola Donini, PhDExecutive Officer
  • Keith L. Brownlie, CPADirector
  • Jerome B. Zeldis, PhDDirector
  • Gregg A. LaPointe, CPADirector
  • Robert J. Rubin, MDDirector
  • R. Christopher Cavalli, PhDExecutive Officer
  • Marco M. Brughera, DVMDirector
  • Christopher J. Schaber, PhDExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
Finders' fees
$137.5K
Placement agents
Aegis Capital Corp.
First sale
Nov 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Medscape99 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Soligenix for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 11 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$150K
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$1.5M
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$300K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$225K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$600K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$300K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$509.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2006$470.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2003$149.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Soligenix ends HyBryte program, faces Nasdaq listing risk | SNGX Quarterly Report (10-Q)stocktitan.net · Aug 2026Soligenix Announces Recent Updates and Second Quarter 2026 Financial Resultsprnewswire.com · Aug 2026Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccineprnewswire.com · Jun 2026Soligenix (NASDAQ: SNGX) raises ATM ceiling to $2.96M under Sales Agreementstocktitan.net · May 2026Soligenix (NASDAQ: SNGX) raises at-the-market stock capacity by $2.96Mstocktitan.net · May 2026Soligenix raises at‑market share capacity by $2.956M under sales agreementtradingview.com · May 2026

Frequently asked questions

What does Soligenix do?
Soligenix is a biopharmaceutical company developing treatments for rare diseases, with programs in photodynamic therapy for cutaneous T-cell lymphoma and psoriasis, immunomodulatory drugs for inflammatory conditions, and vaccine candidates for infectious diseases. The company operates through two segments: Specialized BioTherapeutics, focused on advancing HyBryte and related therapies toward commercialization, and Public Health Solutions, which develops vaccines and therapeutics supported primarily by government contracts.
Who are Soligenix's investors?
Soligenix's investors include Pontifax Venture Capital.
How much funding has Soligenix raised?
Soligenix has disclosed $2M raised across 1 round.
Where is Soligenix headquartered?
Soligenix is headquartered in Princeton, US.